Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis

BACKGROUND/AIM: In a randomized controlled trial, lenvatinib was non-inferior to sorafenib in overall survival (OS) of patients with unresectable hepatocellular carcinoma (uHCC). This study aimed to compare the effects of sorafenib and lenvatinib as first-line systemic therapy against uHCC with real...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Na Ryung, Kim, Ju Yeon, Hong, Ji Hoon, Hur, Moon Haeng, Cho, Heejin, Park, Min Kyung, Kim, Jihye, Lee, Yun Bin, Cho, Eun Ju, Lee, Jeong-Hoon, Yu, Su Jong, Yoon, Jung-Hwan, Kim, Yoon Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951695/
https://www.ncbi.nlm.nih.gov/pubmed/35337274
http://dx.doi.org/10.1186/s12876-022-02210-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951695/
https://www.ncbi.nlm.nih.gov/pubmed/35337274
http://dx.doi.org/10.1186/s12876-022-02210-3

Ejemplares similares